SARS-CoV-2 Antigen Rapid Test

Providing an aid in early diagnosis of individuals who are suspected of COVID-19 by their healthcare provider and who are asymptomatic.

To contact us please click here!
Location:Home > ABOUT US > News > ACON receives Emergency Use Authorization (EUA) for its SARS...
ACON receives Emergency Use Authorization (EUA) for its SARS-COV-2 IgG/IgM Rapid Test
Date:2020-12-16 Click:

ACON, a leading global medical device manufacturer, received the Food and Drug Administration (FDA) clearance under the Emergency Use Authorization (EUA) authorization for Acon® SARS-CoV-2 Antibody Rapid Test.


Acon® SARS-CoV-2 Antibody Rapid Test is a lateral flow chromatographic immunoassay for the qualitative detection of antibodies (IgG and IgM) to SARS-CoV-2 (COVID-19) in human serum, plasma, or whole blood.

The test is intended as an aid in identifying individuals with an adaptive response to SARS-CoV-2, indicating a recent or earlier infection. The test is for the detection and differentiation of IgM and IgG antibodies.

Acon® SARS-CoV-2 Antibody Rapid Test has a high sensitivity and specificity and is therefore highly reliable. The Rapid Test can be performed using a small amount of serum, plasma or whole blood specimen. Results are available within 15 minutes of testing.

About ACON 
ACON, founded in 1995, is a privately-owned Diagnostics and Medical Device company. ACON produces a broad range of medical diagnostic and healthcare products that are sold in over 150 countries worldwide. The company continues to expand its product lines through extensive research and development, with the goal of helping improve the health and well-being of patients around the world.

ACON's manufacturing facility is a US FDA registered manufacturer of rapid diagnostic and healthcare products.

To learn more, please visit or contact our sales.